Normal Glucose Regulation and the Pathophysiology of T1DM and T2DM

Normal Glucose Homeostasis

Blood glucose is normally held within a narrow range by the coordinated action of the pancreatic islets of Langerhans. Beta cells secrete insulin in response to rising glucose, largely after meals, while alpha cells secrete glucagon when glucose falls during fasting or exercise. Insulin lowers glucose by promoting glucose uptake into skeletal muscle and adipose tissue (via GLUT4 transporters), stimulating glycogen synthesis in liver and muscle, and suppressing hepatic glucose output (glycogenolysis and gluconeogenesis). Beta cells also co-secrete amylin, which slows gastric emptying and suppresses glucagon after meals, complementing insulin's glucose-lowering action. Glucagon does the opposite: it stimulates hepatic glycogenolysis and gluconeogenesis to release glucose into circulation and protect the brain, which depends on a continuous glucose supply and cannot store its own fuel.

A second layer of control comes from the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), released from the gut after eating. They potentiate glucose-dependent insulin secretion and, in the case of GLP-1, suppress glucagon and slow gastric emptying — the physiologic basis for GLP-1 receptor agonist therapy covered in Chapter 8. When glucose drops too low, counter-regulatory hormones — glucagon, epinephrine, cortisol, and growth hormone — are released in a coordinated cascade to restore normoglycemia and are central to understanding both hypoglycemia recovery and the two overnight glucose patterns discussed below.

Type 1 Diabetes: Autoimmune Beta-Cell Destruction

Type 1 diabetes (T1DM) results from T-cell-mediated autoimmune destruction of pancreatic beta cells, producing an absolute insulin deficiency. It develops in genetically susceptible individuals, strongly linked to HLA-DR3/DR4 genotypes, after an environmental trigger initiates autoimmunity. The process is commonly staged:

• Stage 1 — two or more islet autoantibodies present (GAD65, IA-2, insulin autoantibodies/IAA, ZnT8); normal glucose; asymptomatic
• Stage 2 — autoantibodies present with dysglycemia; still asymptomatic
• Stage 3 — symptomatic hyperglycemia meeting diagnostic criteria; clinical onset

Because insulin secretion is essentially absent by clinical onset, people with T1DM require lifelong exogenous insulin from diagnosis; oral agents that rely on residual beta-cell function are not effective monotherapy. Because autoantibody positivity often precedes symptomatic hyperglycemia by months to years, screening at-risk first-degree relatives for islet autoantibodies can identify Stage 1 or Stage 2 disease before diabetic ketoacidosis develops, though this is not yet part of routine primary-care screening for the general population.

The Honeymoon Period (Partial Remission Phase)

Shortly after diagnosis and insulin initiation, many people with new-onset T1DM experience a partial remission, or "honeymoon," period: surviving beta cells recover some function once glucotoxicity is relieved, temporarily lowering insulin requirements — sometimes dramatically. This phase can last weeks to several months. It is not a cure — autoimmune beta-cell destruction continues in the background, and insulin needs reliably climb again as remaining beta-cell mass declines. A core educator responsibility is counseling people and families not to interpret the honeymoon period as remission or to discontinue insulin, and to keep monitoring glucose closely through the transition so basal and bolus doses can be retitrated as needs rise.

Type 2 Diabetes: Insulin Resistance Plus Relative Deficiency

Type 2 diabetes (T2DM) is a progressive disease driven by two intertwined defects: insulin resistance in muscle, liver, and adipose tissue, and relative, not absolute, insulin deficiency from progressive beta-cell dysfunction. Early on, beta cells compensate with hyperinsulinemia; hyperglycemia emerges only once compensation fails. Multiple organ systems contribute beyond the classic muscle-liver-fat triad, including increased glucagon secretion (alpha cells), a blunted incretin effect (gut), increased renal glucose reabsorption (kidney, via SGLT2), and altered appetite regulation (brain) — collectively why modern T2DM therapy targets so many different pathways, as covered in Chapter 8. Insulin resistance itself often precedes a T2DM diagnosis by years and can be suspected clinically through surrogate markers such as central adiposity and acanthosis nigricans, well before glucose values cross the diagnostic thresholds covered in section 2.2. T2DM is strongly associated with obesity, physical inactivity, and genetic predisposition, and unlike T1DM, most people retain some endogenous insulin secretion, at least initially, which is why lifestyle change and non-insulin agents are viable first-line options.

Dawn Phenomenon vs. Somogyi Effect

Both produce unexplained morning hyperglycemia, but by different mechanisms, and distinguishing between them changes the treatment response:

The distinguishing test is a 2-3 AM glucose check, from a fingerstick or a CGM trace: a normal-to-rising overnight value points to dawn phenomenon, while a low overnight value followed by a rebound points to Somogyi effect. CGM data has shown that a true Somogyi-pattern rebound is less common in practice than once believed, but the discrimination remains a core teaching and testing point precisely because the two patterns call for opposite treatment: increasing insulin for what is actually a Somogyi pattern will worsen nocturnal hypoglycemia, while failing to adjust basal insulin for a true dawn phenomenon leaves morning hyperglycemia uncorrected.